Want to see SNTI full AI Analyst Report?
Top Page
Senti Biosciences
(NASDAQ:SNTI)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.18
▼(-53.59% Downside)
Action:Downgraded
Date:10/17/26
The score is weighed down primarily by very weak financial performance (minimal revenue, heavy losses/cash burn, and negative equity) and a bearish technical trend (price below key moving averages with negative MACD). Corporate events provide some offset via merger/restructuring progress and financing support, but Nasdaq compliance risks and the lack of traditional valuation support keep the overall score low.
Positive Factors
Gene-Circuit Platform
Senti’s gene-circuit platform is designed to make cell and gene therapies sense disease signals and regulate activity, targeting better precision and less off-tumor toxicity. If translated clinically, this architecture could differentiate programs across oncology rather than relying on a single product.
Negative Factors
Minimal Revenue and Large Losses
TTM revenue of roughly $0.04M provides little operating support against a $49.6M net loss. With margins deeply negative and costs far ahead of revenue, the company lacks demonstrated commercial scale, making continued financing important for advancing its programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Gene-Circuit Platform
Senti’s gene-circuit platform is designed to make cell and gene therapies sense disease signals and regulate activity, targeting better precision and less off-tumor toxicity. If translated clinically, this architecture could differentiate programs across oncology rather than relying on a single product.
Read all positive factors
Senti Biosciences (SNTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.77M
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)2.06
Revenue GrowthN/A
EPS Growth80.28%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.77
Shares Outstanding31,145,390
10 Day Avg. Volume2,433,619
30 Day Avg. Volume1,596,922
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap6.04
Enterprise Value/Revenue744.48
Enterprise Value/Gross Profit-27.21
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$58.00K
Senti Biosciences Business Overview & Revenue Model
Company Description
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogr...
Senti Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.00K | 22.00K | 0.00 | 1.98M | 3.29M | 2.29M |
| Gross Profit | -1.50M | -3.62M | 0.00 | 1.98M | 3.29M | 2.29M |
| EBITDA | -46.97M | -57.80M | -54.88M | -61.34M | -45.74M | -52.31M |
| Net Income | -49.56M | -61.44M | -52.79M | -71.06M | -58.21M | -55.32M |
Balance Sheet | ||||||
| Total Assets | 33.10M | 51.22M | 97.84M | 119.48M | 180.79M | 96.70M |
| Cash, Cash Equivalents and Short-Term Investments | 6.46M | 16.42M | 48.28M | 35.93M | 98.56M | 56.03M |
| Total Debt | 20.23M | 28.89M | 33.64M | 37.67M | 37.09M | 22.73M |
| Total Liabilities | 36.51M | 45.63M | 72.19M | 52.57M | 53.53M | 36.33M |
| Stockholders Equity | -3.40M | 5.59M | 25.65M | 66.91M | 127.26M | 60.38M |
Cash Flow | ||||||
| Free Cash Flow | -38.05M | -43.64M | -41.42M | -64.43M | -76.27M | -40.18M |
| Operating Cash Flow | -38.05M | -43.44M | -41.40M | -52.40M | -34.90M | -34.63M |
| Investing Cash Flow | 126.00K | -184.00K | 34.00K | 30.08M | -81.96M | -5.54M |
| Financing Cash Flow | 20.72M | 11.76M | 53.73M | 779.00K | 118.55M | 68.44M |
Senti Biosciences Technical Analysis
Negative
0.39
Price Trends
0.33
Negative
0.54
Negative
0.75
Negative
Market Momentum
-0.03
Positive
26.67
Positive
9.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNTI, the sentiment is Negative. The current price of 0.39 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.33, and below the 200-day MA of 0.75, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 26.67 is Positive, neither overbought nor oversold. The STOCH value of 9.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNTI.
Senti Biosciences Risk Analysis
Senti Biosciences disclosed 116 risk factors in its most recent earnings report. Senti Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Senti Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
SNTI
Senti Biosciences
0.19
-1.81
-90.50%
KPTI
Karyopharm Therapeutics
0.55
-5.64
-91.18%
TVRD
Tvardi Therapeutics
0.97
-4.19
-81.16%
Senti Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsShareholder MeetingsStock Split
Senti Biosciences shareholders approve merger and restructuring moves
Positive
Oct 15, 2026
On October 15, 2026, Senti Biosciences reconvened its virtual 2026 annual stockholder meeting, where investors elected three Class I directors to serve until the 2029 meeting and ratified KPMG LLP as the independent auditor for the 2026 fiscal yea...
M&A TransactionsShareholder Meetings
Senti Biosciences Adjourns Meeting To Seek Merger Support
Neutral
Oct 13, 2026
On October 8, 2026, Senti Biosciences convened its virtual 2026 Annual Meeting of Stockholders but adjourned the session without conducting any business, despite having a quorum present. The company said it needed more time to solicit shareholder ...
Executive/Board Changes
Senti Biosciences Announces Board and Committee Leadership Change
Neutral
Sep 24, 2026
On September 23, 2026, Senti Biosciences disclosed that board member Brenda Cooperstone, Ph.D., resigned from its Board of Directors, effective immediately. At the same time, she stepped down as both a member and Chair of the Board’s Compens...
M&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Senti Biosciences Secures Equity Commitment Amid Merger Plans
Positive
Sep 4, 2026
On September 3, 2026, Senti Biosciences entered into an equity commitment letter with an affiliate of Celadon Partners, under which Celadon agreed to purchase $2.5 million of Senti common stock at a price tied to Nasdaq’s minimum pricing rul...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Senti Biosciences amends securities agreement, adds note tranche
Negative
Sep 2, 2026
On September 1, 2026, Senti Biosciences amended its April 27, 2026 Securities Purchase Agreement to allow Midco’s senior secured convertible notes to be issued in more than two tranches and specifically authorize a $2.0 million third tranche...
Business Operations and StrategyM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Senti Biosciences Advances Proxy for Merger and CVR
Neutral
Aug 20, 2026
On July 21, 2026, Senti Biosciences filed a preliminary proxy statement with the SEC related to several proposed corporate actions, including potential issuances of additional notes beyond an existing exchange cap and a possible merger of a Celado...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.